Clinical Trials

Phase 2 Active not recruiting

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT07480863 2026-04-02

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

65 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT04824092 2026-04-01

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Withdrawn

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT01190930 2026-03-31

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

9,350 enrolled 51 charts

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Phase 3 Recruiting

5,951 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT04529772 2026-03-31

ESCALADE

611 enrolled

Phase 2 Active not recruiting

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05761171 2026-03-31

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

78 enrolled

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04747912 2026-03-30

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Phase 2 Suspended

25 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00428142 2026-03-27

Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Phase 2 Completed

95 enrolled

Lymphoma, Lymphoma, Follicular

NCT07493148 2026-03-25

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Phase 2 Recruiting

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05888493 2026-03-24

LEDA

109 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT02405676 2026-03-19

BNHL-2015

200 enrolled

Lymphoma

NCT02845882 2026-03-18

LBL-2016 for Children or Adolescents in China

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06207123 2026-03-18

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Phase 1/2 Recruiting

15 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT02166463 2026-03-17

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

600 enrolled 14 charts 1 FDA

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT06918431 2026-03-17

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2 Recruiting

53 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00006721 2026-03-16

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3 Completed

571 enrolled 12 charts

Lymphoma, Lymphoma, Follicular

NCT05453500 2026-03-13

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

30 enrolled